Literature DB >> 24739050

Adenocarcinoma of the rete testis - a rare case of testicular malignancy.

M Chovanec, M Mego, Z Sycova-Mila, J Obertova, J Rajec, P Palacka, J Mardiak.   

Abstract

BACKGROUND: Adenocarcinoma of rete testis is an extremely rare dia-gnosis described in around 70 patients worldwide. The prognosis of the disease in metastatic stage is very poor and there is no standard systemic treatment available. CASE: Herein we present a unique case report of a 47-year- old man with metastatic adenocarcinoma of rete testis who achieved substantial disease response after four cycles of paclitaxel, ifosfamide and cisplatin. The chemotherapy was administered in five -day regimen, which comprised 250 mg/ m2 of paclitaxel on day one, 20 mg/ m2 of cisplatin on day one to five and 1,2 g/ m2 of ifosfamide on day one to five, in a three-week interval. The patient received prophylactic pegfilgrastim after each cycle of TIP. The treatment was well tolerated -  without any significant toxicity. RESULT: Patient achieved a partial 14- month remission.
CONCLUSION: On basis of this experience we suggest that paclitaxel, ifosfamide and cisplatin might be adopted as novel agents in treatment of rete testis adenocarcinoma.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24739050     DOI: 10.14735/amko2014136

Source DB:  PubMed          Journal:  Klin Onkol        ISSN: 0862-495X


  2 in total

1.  Primary adenocarcinoma of the rete testis with elevated serum CA19-9 antigen levels.

Authors:  Hiroyuki Kitano; Kazuhiro Sentani; Keisuke Goto; Yohei Sekino; Ryoken Yamanaka; Keiji Nagasaka; Yoshinori Shigematsu; Kanao Kobayashi; Tetsutaro Hayashi; Wataru Yasui; Jun Teishima
Journal:  Int Cancer Conf J       Date:  2020-08-09

2.  Aggressive surgical management of adenocarcinoma of the rete testis.

Authors:  Avinash Maganty; Anisleidy Fombona; Jathin Bandari; Timothy D Lyon; Scott Kulich; Jeffrey R Gingrich; Joel D Bigley; Tatum V Tarin
Journal:  Urol Case Rep       Date:  2017-11-13
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.